Dr. Agarwal's Health Care Limited — Q1FY27 earnings call summary

Filed 04 August 2026 · Company audio recording

One-time brand ambassador and production costs (~Rs 13.5 cr total) impacted margins in FY25; no recurring production costs expected
Capex guidance for FY26 at Rs 310 cr (new centers, tech upgrades, maintenance); additional Rs 70-80 cr for flagship facility
EBITDA margin expected to remain stable despite greenfield investments
FY26 revenue growth targeted at 20%+ driven by network expansion and high-end surgery adoption
Plan to add 55-60 new facilities in FY26; 25-30 surgical, rest clinics; 70% expansion in southern states + Maharashtra
PAT expected to grow 35%+ in FY26
FY25 EBITDA margin at 28.6%; Q4 margin improved to 30.8% despite higher manpower and marketing costs
Installed FEMTO laser cataract machines in key metros; plan to add SMILE technology for refractive surgeries